Response to: "Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication".
Rick JW, Lio P, Hsiao JL, Shi VY. Response to: "Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication". J Am Acad Dermatol. 2022 07; 87(1):e33-e34.